Avalo Therapeutics, Inc.
AVTX
$19.52
$0.070.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -117.10% | -216.06% | -122.78% | -1,155.06% | -27.59% |
| Total Depreciation and Amortization | -70.62% | -16.30% | 103.55% | 175.00% | 145.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 693.32% | 118.86% | 340.90% | 277.02% | -147.39% |
| Change in Net Operating Assets | 146.25% | 169.62% | 181.58% | 176.12% | 143.82% |
| Cash from Operations | -44.02% | -14.11% | -4.90% | -42.08% | -47.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -344.93% | -- | -- | -- | -- |
| Cash from Investing | -344.93% | -- | -23,055.06% | -23,729.49% | -20,004.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 553.84% | -74.46% | -91.59% | -27.48% | -50.92% |
| Repurchase of Common Stock | -53.24% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,449.31% | 79.06% | 94.99% | 76.83% | 76.83% |
| Cash from Financing | 534.54% | -76.22% | -91.70% | -24.53% | -43.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 184.44% | -769.44% | -193.27% | -176.36% | -158.59% |